If I'm reading that first graph correctly, which is for the whole tested population, the averaged pain reduction for iPPS is only at best about 6% less than the placebo. So what I'm interpreting is that for some severe pain sufferers a more substantial reduction is found ( previous announcement) , but averaged out over the whole population tested it does not look to be too impressive. Or am I dead wrong?
Ann: Paradigms Supplementary Phase 2B Data, page-4
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $129.3K | 520.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59256 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 35769 | 8 |
View Market Depth
| Last trade - 15.18pm 11/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |